Lex Diagnostics has started commercialization of Velo, an FDA 510(k)‑cleared and CLIA‑waived cartridge‑based qPCR system that yields sample‑to‑answer results in roughly 10 minutes for flu and COVID targets. The Velo system uses ultra‑fast thermal cycling through flat reaction chambers and novel chemistries to achieve extremely rapid PCR without increasing reagent concentrations. The company says cartridges are inexpensive to manufacture and the platform is designed for point‑of‑care use in clinics and urgent care settings, where clinicians increasingly demand actionable molecular results within the timeframe of a patient visit. Lex reported production capacity and early commercial scale‑up plans, positioning Velo against other fast MDx systems that target clinic workflows. If uptake matches claims, the device could compress diagnostic pathways for respiratory infections, reduce empirical prescribing, and reinforce the trend toward molecular testing at the bedside.